A Novel Metabolic Target (CD59) for Obesity, Insulin Resistance, and Fatty Liver npj Metabolic Health and Disease | June 2026

Introduction:

Obesity, insulin resistance, and metabolic dysfunction-associated steatotic liver disease (MASLD) are closely linked metabolic disorders with limited disease-modifying therapies. This study identifies CD59, traditionally known as a complement regulatory protein, as a previously unrecognized driver of metabolic dysfunction.

Why was this study needed?

• New molecular targets are needed to treat obesity and MASLD.
• The role of immune regulatory proteins in metabolic disease remains poorly understood.
• Chronic inflammation is a major contributor to metabolic dysfunction.
• The relationship between the complement system and metabolism requires further investigation.
• Novel pathways may lead to future metabolic therapies.

Results:

• CD59-deficient mice were protected against diet-induced obesity, insulin resistance, glucose intolerance, hyperinsulinemia, and fatty liver, despite consuming a high-fat diet.
• Loss of CD59 improved the metabolic profile by reducing appetite, increasing physical activity, raising adiponectin levels, and lowering leptin levels.
• Liver inflammation and fibrosis were markedly reduced, identifying CD59 as a novel regulator of metabolic and hepatic injury.

Clinical Impact:

This study uncovers an unexpected role for CD59 beyond complement regulation, linking it directly to obesity and MASLD pathogenesis. Although these findings are currently limited to animal models, CD59 inhibition may represent a promising therapeutic strategy for obesity, insulin resistance, and fatty liver disease.

Bottom Line:

CD59 is more than a complement regulator—it is a novel metabolic driver. Targeting CD59 may offer a new approach to prevent or treat obesity, insulin resistance, and MASLD, opening an exciting avenue for future metabolic therapies.